Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Roberts Glore & Co. Inc. IL

Roberts Glore & Co. Inc. IL decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,088 shares of the pharmaceutical company’s stock after selling 67 shares during the quarter. Roberts Glore & Co. Inc. IL’s holdings in Vertex Pharmaceuticals were worth $1,646,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Dunhill Financial LLC raised its holdings in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares in the last quarter. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Truvestments Capital LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $35,000. Finally, Capital Performance Advisors LLP acquired a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $39,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $475.34, for a total value of $251,930.20. Following the completion of the sale, the executive vice president now owns 58,539 shares of the company’s stock, valued at approximately $27,825,928.26. This trade represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 1,084 shares of company stock valued at $505,512. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $488.29 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The stock has a fifty day moving average price of $448.27 and a 200 day moving average price of $461.32. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a market cap of $125.39 billion, a PE ratio of -221.95, a P/E/G ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Bank of America dropped their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research note on Thursday, December 19th. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and increased their price target for the company from $408.00 to $424.00 in a research note on Tuesday, February 11th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.